

Supplemental online content for:

Addition of Definitive Radiotherapy to Chemotherapy in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer

*Vivek Verma, MD; Pamela K. Allen, PhD; Charles B. Simone II, MD; Hiram A. Gay, MD;
and Steven H. Lin, MD, PhD*

J Natl Compr Canc Netw 2017;15(11):1383–1391

eTable 1: Cox Proportional Hazards Model for Overall Survival

eTable 1. Cox Proportional Hazards Model for Overall Survival				
Parameter, N (%)	Univariate		Multivariate ^a	
	HR (95% CI)	P Value	HR (95% CI)	P Value
Age (continuous)	1.01 (1.00–1.02)	.002		
Sex				
Male	Ref	Ref		
Female	0.92 (0.71–1.19)	.513		
Race				
White	Ref	Ref		
Black	1.15 (0.86–1.54)	.353		
Hispanic	1.02 (0.73–1.44)	.898		
Other	0.76 (0.58–1.00)	.053		
Insurance type				
Private	0.71 (0.49–1.03)	.069	0.93 (0.63–1.39)	.736
Medicare	1.29 (0.88–1.89)	.199	1.49 (1.00–2.22)	.053
Medicaid	1.07 (0.71–1.62)	.746	1.17 (0.77–1.80)	.461
Other governmental	1.06 (0.33–3.45)	.924	0.72 (0.21–2.46)	.602
Uninsured	Ref	Ref	Ref	Ref
Unknown	0.71 (0.36–1.39)	.314	0.74 (0.37–1.49)	.401
Annual income (USD)				
<\$48,000	Ref	Ref	Ref	Ref
≥\$48,000	0.80 (0.65–0.99)	.043	0.80 (0.64–1.01)	.060
Location				
Metropolitan	Ref	Ref		
Urban	1.28 (0.93–1.75)	.134		
Rural	1.91 (0.79–4.65)	.152		
Facility type				
Community	Ref	Ref		
Academic/Research-Integrated Network	0.85 (0.68–1.06)	.152		
Facility location				
New England	Ref	Ref		
Middle Atlantic	1.38 (0.71–2.67)	.340		
South Atlantic	1.53 (0.81–2.93)	.193		
East North Central	1.76 (0.92–3.40)	.090		
East South Central	1.63 (0.80–3.30)	.176		
West North Central	1.15 (0.54–2.47)	.711		
West South Central	1.79 (0.89–3.57)	.100		
Mountain	1.96 (0.86–4.44)	.108		
Pacific	1.16 (0.61–2.23)	.654		
Distance to treating facility (continuous)	1.00 (1.00–1.00)	.995		
Year of diagnosis (continuous)	0.99 (0.95–1.04)	.808		
Adults in zip code without high school diploma (%)				
≥21%	Ref	Ref		
13%–20.9%	1.00 (0.76–1.32)	.978		
7%–12.9%	0.93 (0.70–1.25)	.648		
<7%	0.81 (0.57–1.15)	.241		
Charlson-Deyo score				
0	Ref	Ref	Ref	Ref
1	1.62 (1.21–2.15)	.001	1.44 (1.07–1.94)	.016
≥2	2.22 (1.27–3.88)	.005	2.49 (1.36–4.59)	.003
Tumor grade				
Well-differentiated	Ref	Ref		
Moderately differentiated	0.56 (0.25–1.27)	.164		
Poorly differentiated	0.37 (0.17–0.80)	.011		
Undifferentiated	0.32 (0.15–0.70)	.004	0.66 (0.47–0.93)	.016
Unknown	0.45 (0.21–0.96)	.04		
T stage				
0				
1				
2	1.23 (0.85–1.77)	.273		
3	1.15 (0.81–1.64)	.431		
4	1.35 (0.98–1.84)	.065		
Unknown	1.62 (1.12–2.36)	.011		
N stage				
0	Ref	Ref		
1	0.66 (0.44–1.01)	.056		
2	0.80 (0.54–1.18)	.260		
3	0.83 (0.54–1.27)	.397		
Unknown	0.91 (0.60–1.40)	.682		
Receipt of radiotherapy				
Yes	0.51 (0.41–0.63)	<.001	0.50 (0.40–0.63)	<.001
No	Ref	Ref	Ref	Ref

Statistically significant P values are in bold.

Abbreviation: HR, hazard ratio.

^aMultivariate analysis contains factors present in the final model.